VAXX — Vaxxinity Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Vaxxinity Announces Intention To Voluntarily Delist And Deregister Its Class A Common Stock
Brief: Vaxxinity Announces Intention To Voluntarily Delist And Deregister Its Class A Common Stock
Brief: Vaxxinity Q4 Net Income USD -11.392 Million
Vaxxinity Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Vaxxinity - On Feb 9 Got Notice From Nasdaq That Co Is No Longer In Compliance With Minimum Bid Price Requirement For Continued Listing
Brief: Vaxxinity’S Cholesterol Vaccine Candidate Successfully Lowers Ldl-C Preclinical Data Published
Brief: Vaxxinity Announces Collab On Space Medicine Research With University Of Central Florida
Focus: Researchers return to Alzheimer's vaccines, buoyed by recent drug success
Brief: Vaxxinity Q3 Net Income USD -13.145 Million
Vaxxinity Inc reports results for the quarter ended in June - Earnings Summary
Brief: Vaxxinity Inc Files For Mixed Shelf Of Up To $300 Million - SEC Filing
Vaxxinity Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Vaxxinity Appoints Peter Powchik, M.D., To Executive Vice President, Global Scientific Director
Vaxxinity up as Parkinson's disease vaccine met early-stage study goal
Brief: Vaxxinity Announces UB-312 Successfully Met Primary Objectives Of Phase 1 Clinical Trial In Parkinson’s Disease
Brief: Vaxxinity Reports Q1 Financial Results
Vaxxinity Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Vaxxinity Reports Q4 Loss Per Share Of $0.16
Brief: Vaxxinity Announces First Subjects Dosed In Phase 1 Clinical Trial Of Vxx-401, Investigational Anti-Pcsk9 Vaccine To Treat Hypercholesterolemia